Measuring the methylation status of cell-free DNA (cfDNA) in plasma holds great potential for the early, noninvasive detection of cancer. Two recent papers published in Nature Medicine showcase the successful application of cfDNA methylation-based cancer detection to two highly challenging scenarios.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial
BMC Medicine Open Access 05 November 2025
-
Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Scientific Reports Open Access 19 August 2023
-
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
Clinical Epigenetics Open Access 02 December 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nassiri, F. et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nat. Med. 26, 1044–1047 (2020).
Nuzzo, P. V. et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat. Med. 26, 1041–1043 (2020).
Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl Med. 6, 224ra24 (2014).
Zill, O. A. et al. The landscape of actionable genomic alterations in cell-free circulating tumor DNA from 21,807 advanced cancer patients. Clin. Cancer Res. 24, 3528–3538 (2018).
Reynard, J., Brewster, S. & Biers, S. Oxford Handbook of Urology (Oxford University Press, 2013).
Gill, I. S., Aron, M., Gervais, D. A. & Jewett, M. A. S. Small renal mass. N. Engl. J. Med. 362, 624–634 (2010).
Kang, S. et al. CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA. Genome Biol. 18, 53 (2017).
Shen, S. Y., Burgener, J. M., Bratman, S. V. & De Carvalho, D. D. Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA. Nat. Protoc. 14, 2749–2780 (2019).
Acknowledgements
The authors’ work is supported by the NIH grants U01CA230705, R01CA246329, and U01CA237711.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W.L. and X.J.Z. are co-founders and shareholders of EarlyDiagnostics Inc.
Rights and permissions
About this article
Cite this article
Li, W., Zhou, X.J. Methylation extends the reach of liquid biopsy in cancer detection. Nat Rev Clin Oncol 17, 655–656 (2020). https://doi.org/10.1038/s41571-020-0420-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41571-020-0420-0
This article is cited by
-
The role of dynamic monitoring of plasma cell-free DNA methylation in predicting pathological response in resectable stage IIB-IIIB non-small cell lung cancer: biomarker analyses from a prospective phase II trial
BMC Medicine (2025)
-
Advances in methylation analysis of liquid biopsy in early cancer detection of colorectal and lung cancer
Scientific Reports (2023)
-
Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
Clinical Epigenetics (2022)
-
Multi-omic characterization of genome-wide abnormal DNA methylation reveals diagnostic and prognostic markers for esophageal squamous-cell carcinoma
Signal Transduction and Targeted Therapy (2022)
-
Current challenges in metastasis research and future innovation for clinical translation
Clinical & Experimental Metastasis (2022)
